Matthew Ronsheim
Corporate Officer/Principal presso ENTASIS THERAPEUTICS HOLDINGS INC.
Patrimonio netto: 639 653 $ in data 31/05/2024
Posizioni attive di Matthew Ronsheim
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 | - |
Storia della carriera di Matthew Ronsheim
Precedenti posizioni note di Matthew Ronsheim
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 01/06/2016 | 01/08/2019 |
| Corporate Officer/Principal | 01/06/2016 | 01/08/2019 |
Formazione di Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Matthew Ronsheim
- Esperienza
